Introduction {#s1}
============

Bladder cancer (BLCA) is the most common malignancy of the urinary system with high morbidity and mortality rates ([@B1]). Approximately 25% of BLCA patients are diagnosed with muscle-invasive or metastatic disease during the early stages of prognosis ([@B2]). Meanwhile patients with non-muscle-invasive BLCA continue to suffer from the high progression rates ([@B3]; [@B4]). Overall, the 5-year survival rate at all stages of bladder cancer remains no more than 20% ([@B5]). Once the tumor progresses to locally advanced or metastatic stage, standard treatment for BLCA with combination chemotherapy are insufficient with low response and survival rates ([@B7]; [@B6]). With the emergence of immune checkpoint therapy including programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1), the treatment of advanced BLCA patients with durable response has become possible ([@B8]). However, most BLCA patients do not adequately respond to PD-1 or PD-L1-targeted therapy; and hence, it is imperative to develop prognostic biomarkers to closely monitor progression and shed light on treatment stratification.

The most representative of BLCA type is urothelial cancer (UC). Up to 30% of urothelial cancer (UC) specimens have demonstrated differential expression in PD-L1, which is associated with increased all-cause mortality ([@B11]; [@B9]; [@B10]). However, standalone PD-L1 expression acts as an unviable biomarker since significant heterogeneity of association were observed between PD-L1 staining and clinical results of BLCA patients ([@B14]; [@B12]; [@B13]; [@B15]; [@B16]). Since PD-L1 expression is subject to immunohistochemistry (IHC) score; the expression of immune-related gene (IRG) may serve as a better biomarker as it can be quantified from multiple cell types within a sample ([@B17]). In this context, the IRG-based prognostic signatures have been proposed for patients diagnosed with nonsquamous non--small cell lung cancer ([@B18]) and papillary thyroid cancer ([@B19]), which show significant prognostic values. However, the clinical relevance and prognostic significance of IRGs-based signature in BLCA remains unknown.

The purpose of the present study was to investigate the clinical implications of IRGs on prognostic stratification and their potential as biomarkers for targeted BLCA therapy. In the manuscript, we performed integrated analysis using IRG expression profiles and clinical information of patients with BLCA retrospectively. Individualized prognostic signature based on IRGs was developed and validated in independent datasets, while underlying mechanisms were explored using bioinformatics analysis.

Materials and Methods {#s2}
=====================

Data Source {#s2_1}
-----------

From The Cancer Genome Atlas (TCGA), normalized RNA sequencing (RNA-Seq) data sets with estimation of Fragments Per Kilobase of transcript per Million mapped reads (FPKM) from 414 tumor samples and 19 non-tumor samples were retrieved. Clinical data were also derived from TCGA into integrated analysis. Gene expression data and clinical information in GSE13507 based on the Illumina human-6 v2.0 expression BeadChip platform were downloaded from gene expression omnibus (GEO) database (<https://www.ncbi.nlm.nih.gov/geo/>). A total of 568 patients were involved in the development and validation of the prognostic signature, i.e., 403 patients in TCGA dataset and 165 patients in GSE13507 cohort.

Data Preprocessing and Differential Analysis {#s2_2}
--------------------------------------------

In the R software, differentially expressed genes (DEGs) between BLCA and normal tissues were identified using Wilcoxon test after within-array replicate probes were replaced with their average *via limma* package ([@B21]; [@B20]). The p-value was adjusted with the false discovery rate (FDR) ([@B22]). FDR \< 0.05 and \|log2(FC)\| value \> 1 was considered significant.

The Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@B23]) pathway enrichment were analyzed with the DEGs using the *clusterProfiler* R package ([@B24]). P \< 0.05 was considered statistically significant.

Development and Validation of a Prognostic Signature {#s2_3}
----------------------------------------------------

By accessing the Immunology Database and Analysis Portal (IMMPORT) ([@B25]) website (<https://www.immport.org>), we retrieved a latest list of immune‐related genes, out of which we identified BLCA-specific immune‐related genes (IRGs) after matching the DEGs. Survival-associated IRGs were identified using univariate Cox regression analysis with a threshold value of p \< 0.01.

Patients in TCGA dataset was randomly assigned in a 7:3 ratio to a training set and test set with the same proportion of each BLCA stage. With expression profiles of the identified survival-associated IRGs, we conducted least absolute shrinkage and selection operator (LASSO) regression analysis in the training set. Subsequently we calculated the individualized risk score with coefficients and constructed a prognostic signature which separates the high-risk BLCA patients from the low-risk group. Clinical relevance was validated using survival analysis between groups with thresholds of p \< 0.05 using the R software survival and survminer package; whereas, the receiver operating characteristic (ROC) analysis was performed (*via* the survival ROC package), and the area under the curve (AUC) was calculated at multiple time-point to evaluate the discrimination ([@B26]).

Clinical characteristics including age, gender, stage, and tumor-node-metastasis (TNM) status were collected from TCGA database and integrated with transcriptome profile derived from TCGA dataset. Multivariate cox regression analysis was performed using clinical data and risk scores to see if the prognostic value of risk scores was independent of clinical characteristics. A value of p \< 0.05 was considered significant statistically.

External Validation of the Prognostic Signature in the Test Set and GSE13507 Cohort {#s2_4}
-----------------------------------------------------------------------------------

The prognostic signature with the same risk score formula and cutoff value was then validated in the test set and external dataset GSE13507 respectively. We chose the GSE13507 as it involved the largest sample size of BLCA patients with survival data. Likewise, the prognostic model was presented as a risk plot in each dataset that encompassed the expression level of the included genes, distribution of risk score, and survival status of individuals.

Gene Set Enrichment Analysis Analysis {#s2_5}
-------------------------------------

We performed *Gene Set Enrichment Analysis* (GSEA) between high-risk and low-risk group as separated by the 7-IRG signature *via clusterProfiler* and *enrichplot* R package. Two functions (gseGO and gseKEGG) were applied to identify the enriched terms in Gene Ontology (GO) and KEGG with a false discovery rate (FDR) value \< 0.05 ([@B27]).

Difference of Tumor-Infiltrating Immune Cells Between Groups Defined by the Signature in Bladder Cancer {#s2_6}
-------------------------------------------------------------------------------------------------------

Six types of tumor-infiltrating immune cells were retrieved from Tumor Immune Estimation Resource (TIMER) (<https://cistrome.shinyapps.io/timer/>), ([@B28]) also known as a web server for comprehensive analysis of tumor-infiltrating immune cells. The abundance of immune cells was tested one by one to detect the differences between the prognostic classified risk groups using Wilcoxon test.

Construction of a Nomogram Based on the Immune-Related Gene Signature {#s2_7}
---------------------------------------------------------------------

A nomogram encompassing the risk score based on expression of prognostic IRGs and clinicopathological factors was constructed using the *rms* R package. Discrimination of the nomogram was validated using ROC analysis at 3- and 5-year follow-up, and predictive accuracy was tested by presenting the difference between predicted survival and actual survival using calibration plot. Further, decision curve analysis (DCA) was performed to examine the clinical utility of the nomogram by quantifying the net benefits at different threshold probabilities.

Results {#s3}
=======

Bladder Cancer Specific Immune-Related Genes {#s3_1}
--------------------------------------------

We managed to obtain 4,876 DEGs base on the transcription profile in TCGA dataset, out of which 3,453 genes were upregulated and 1,423 downregulated. The DEGs were presented in [**Supplementary Material S1**](#SM1){ref-type="supplementary-material"}. The KEGG analysis ([**Figure 1**](#f1){ref-type="fig"}) indicated that the genes were mainly involved in PI3K−Akt and MAPK signaling pathway, which are pivotal in the regulation of immune responses ([@B30]; [@B29]). Specific IRGs were identified with intersection of the immune-related genes and DEGs in BLCA. As shown in [**Figure 2**](#f2){ref-type="fig"}, we identified 120 upregulated, and 140 downregulated BLCA-specific IRGs.

![The top 30 most enriched Kyoto Encyclopedia of Genes and Genomes pathways.](fgene-11-00012-g001){#f1}

![Differentially expressed immune‐related genes. Heatmap **(A)** and a volcano plot **(B)**.](fgene-11-00012-g002){#f2}

Development and Internal Validation of a Prognostic Signature {#s3_2}
-------------------------------------------------------------

A total of 403 patients with BLCA in TCGA dataset was recorded with follow-up time \>0. Based on the data in these patients, totally 47 survival-associated IRGs were identified using univariate Cox regression. [**Table 1**](#T1){ref-type="table"} shows the general profile of survival-associated IRGs in BLCA. Subsequently, we split TCGA dataset randomly into training set (n = 284) and test set (n = 119). With expression profiles of survival-associated IRGs, we conducted a LASSO regression in the training set and identified seven BLCA-specific prognostic IRGs ([**Figures 3A, B**](#f3){ref-type="fig"}). The boxplot of expression levels of these genes between BLCA and normal samples in TCGA dataset along with results of Wilcoxon test is provided in [**Supplementary Material S2**](#SM2){ref-type="supplementary-material"}.

###### 

Characteristics of bladder cancer‐specific immune‐related genes (univariate cox analysis).

  id        HR       HR.95L   HR.95H   p value
  --------- -------- -------- -------- ---------
  PTGER3    1.3982   1.2271   1.5932   0.0000
  TACR1     1.5641   1.2256   1.9961   0.0003
  IGF1      1.3292   1.1747   1.5039   0.0000
  GHR       1.2524   1.0956   1.4317   0.0010
  SLIT2     1.1783   1.0856   1.2790   0.0001
  NR3C2     1.1619   1.0673   1.2648   0.0005
  GLP2R     1.1511   1.0672   1.2416   0.0003
  AGTR1     1.1437   1.0661   1.2270   0.0002
  FGF10     1.1685   1.0575   1.2911   0.0022
  SEMA3E    1.2198   1.0529   1.4131   0.0081
  NGF       1.1376   1.0521   1.2300   0.0012
  EDNRA     1.0914   1.0496   1.1349   0.0000
  ADIPOQ    1.0894   1.0438   1.1369   0.0001
  SEMA3A    1.1546   1.0428   1.2785   0.0057
  PDGFD     1.0752   1.0370   1.1149   0.0001
  NFATC1    1.1038   1.0299   1.1830   0.0052
  AKT3      1.0724   1.0284   1.1183   0.0011
  IL17RD    1.0712   1.0245   1.1201   0.0025
  PDGFRA    1.0444   1.0213   1.0680   0.0001
  ILK       1.0637   1.0204   1.1088   0.0036
  NFATC4    1.0614   1.0195   1.1050   0.0037
  NRP2      1.0482   1.0189   1.0784   0.0011
  KCNH2     1.0335   1.0188   1.0484   0.0000
  IL34      1.0409   1.0156   1.0667   0.0014
  ANGPTL1   1.0294   1.0133   1.0457   0.0003
  OGN       1.0280   1.0131   1.0430   0.0002
  RAC3      1.0239   1.0130   1.0350   0.0000
  PAEP      1.0410   1.0124   1.0704   0.0047
  PGF       1.0297   1.0118   1.0480   0.0011
  S1PR1     1.0300   1.0084   1.0521   0.0063
  PPY       1.0169   1.0078   1.0261   0.0003
  AHNAK     1.0119   1.0077   1.0160   0.0000
  TGFBR2    1.0173   1.0076   1.0271   0.0005
  ELN       1.0183   1.0075   1.0292   0.0009
  NAMPT     1.0135   1.0070   1.0201   0.0000
  RBP7      1.0134   1.0069   1.0199   0.0001
  CXCL12    1.0117   1.0060   1.0175   0.0001
  ANXA6     1.0094   1.0040   1.0149   0.0006
  PTX3      1.0095   1.0037   1.0153   0.0012
  THBS1     1.0018   1.0007   1.0029   0.0017
  CSRP1     1.0019   1.0005   1.0034   0.0089
  TPM2      1.0010   1.0003   1.0016   0.0056
  A2M       1.0012   1.0003   1.0021   0.0098
  MMP9      1.0002   1.0001   1.0004   0.0093
  TAP1      0.9950   0.9915   0.9986   0.0061
  OAS1      0.9855   0.9769   0.9942   0.0011
  SH3BP2    0.8812   0.8154   0.9523   0.0014

![Development of the prognostic signature based on seven immune‐related genes (IRGs) in the training set. **(A, B)** LASSO regression identified 7 IRGs **(C)** Time-dependent ROC curve of the 7-IRG prognostic signature **(D)** Survival analysis between signature-defined risk groups **(E)** Heatmap of expression profiles of included IRGs **(F)** Distribution of groups based on the signature **(G)** Survival status of patients in different groups.](fgene-11-00012-g003){#f3}

After extracting the coefficient values, we calculated individualized risk scores with coefficient‐weighted expression levels of seven IRGs with the following formula:
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The median of the risk score is 0.24. Individuals with a risk score higher than 0.24 were classified as a high-risk group while the other as a low-risk group; consequently, a prognostic signature based on seven IRGs was developed. The survival analysis indicated that the survival rate was remarkably lower in the high‐risk group as opposed to low‐risk group \[hazard ratio (HR) = 10, 95% confidence interval (CI) = 5.6--19, p-value \<0.001, [**Figure 3C**](#f3){ref-type="fig"}\]; whereas, the ROC curve analysis ([**Figure 3D**](#f3){ref-type="fig"}) showed acceptable discrimination with AUCs of 0.711, 0.754, and 0.772 at 1-, 3-, and 5-year follow-up respectively. [**Figures 3E--G**](#f3){ref-type="fig"} represents the risk plot encompassing distribution of groups based on the signature, survival status of individuals between groups, and the expression level of included IRGs. It shows a clear separation of survival status between risk groups with red dots being death and blue ones alive. While a large amount of death occurred in the high-risk group, most of the patients in low-risk group stayed alive at follow-up.

We calculated individual risk score with the aforementioned formula and classified the patients in the test set into high-risk and low-risk groups. Similarly, we validated the clinical utility and discrimination in both datasets. [**Figure 4**](#f4){ref-type="fig"} summarizes the results of validation in the test set. A significant separation was shown in the Kaplan-Meier survival curve in the test set (HR = 6.9, 95% CI = 1.8--27, p-value = 0.01, [**Figure 4A**](#f4){ref-type="fig"}). ROC curve analysis demonstrated acceptable discrimination with an AUC of 0.68 in predicting 5-year overall survival ([**Figure 4B**](#f4){ref-type="fig"}). Meanwhile, the risk plot shows markedly different survival status between groups ([**Figures 4C--E**](#f4){ref-type="fig"}).

![Validation of the the seven immune‐related gene (7-IRG) prognostic signature in the test set. **(A)** Time-dependent receiver operating characteristic (ROC) curve of the 7-IRG prognostic signature. **(B)** Survival analysis between signature-defined risk groups. **(C)** Heatmap of expression profiles of included IRGs. **(D)** Distribution of groups based on the signature. **(E)** Survival status of patients in different groups. **(F)** Multivariable analyses of the risk score, age, gender, tumor stage, and T/N/M, where confidence interval (CI) and hazard ratio (HR) stand for a confidence interval, and hazard ratio, respectively.](fgene-11-00012-g004){#f4}

Multivariate Cox regression analysis with TCGA dataset suggested that the 7-IRG based prognostic signature could be an independent predictor after other variables including age, gender, stage, and information coded in TNM concerning status of tumor, lymph node, and distant metastasis were adjusted ([**Figure 4F**](#f4){ref-type="fig"}).

External Validation in the Test and GSE13507 Datasets {#s3_3}
-----------------------------------------------------

In GSE13507 cohort, we validated the IRG-based prognostic signature for overall survival, cancer specific survival and progression-free survival using the same formula and cutoff value. The results were presented in [**Figure 5**](#f5){ref-type="fig"} with Kaplan-Meier curve and time-dependent ROC curve. Consistent with above findings, significantly different survival outcomes were observed between risk groups in overall survival (OS) (HR = 73,000, 95% CI = 0.53--10\^10, p-value = 0.01, [**Figure 5A**](#f5){ref-type="fig"}), cancer-specific survival (CSS) (HR = 8.4\*10\^9, 95% CI = 2,700--2.6\*10\^16, p-value \<0.001, [**Figure 5B**](#f5){ref-type="fig"}), and progression-free survival (PFS) (HR = 1.3\*10\^8, 95% CI = 11-1.7\*10\^15, p-value = 0.02, [**Figure 5C**](#f5){ref-type="fig"}). Similarly, ROC curve analysis indicated that the prognostic signature can effectively predict 65% of the overall survival, 71% of the cancer specific survival, and 71% of the progression-free survival at 1- and 3-year follow-up ([**Figures 5D, E**](#f5){ref-type="fig"}). Risk plots for different survival indicators were presented in [**Supplementary Material S3**](#SM3){ref-type="supplementary-material"}.

![Validation of the the seven immune‐related gene (7-IRG) prognostic signature in GSE13507 cohort. **(A--C)** Survival analysis between signature-defined risk groups \[overall survival (OS) **(A)**, cancer-specific survival (CSS) **(B)**, and progression-free survival (PFS) **(C)**\]. **(D--F)** Time-dependent receiver operating characteristic (ROC) curve for predicting survival of the 7-IRG prognostic signature \[OS **(D)**, CSS **(E)**, and PFS **(F)**\].](fgene-11-00012-g005){#f5}

Gene Set Enrichment Analysis {#s3_4}
----------------------------

The predictive performance of the 7-IRG signature could be associated with the biological function of these IRGs in BLCA. To explore the underlying mechanism, we performed GSEA between high-risk and low-risk groups based on the signature to identify the enriched GO term as well as KEGG pathway. [**Figure 6**](#f6){ref-type="fig"} shows the results of enrichment analysis. GO terms ([**Figure 6A**](#f6){ref-type="fig"}) including collagen−activated tyrosine kinase receptor signaling pathway, dendritic cell antigen processing and presentation, extracellular matrix component, as well as leukocyte migration and chemotaxis involved in inflammatory response were significantly enriched. In the case of KEGG pathway ([**Figure 6B**](#f6){ref-type="fig"}), we found enhanced activity of several immune-related pathways in the high-risk group, such as chemokine signaling pathway, cytokine−cytokine receptor interaction, ECM−receptor interaction, IL−17 signaling pathway, leukocyte transendothelial migration, and PI3K−Akt signaling pathway. Particularly, upregulated PI3K−Akt pathway was in consistency with the KEGG enrichment of DEGs between tumor and control specimens in BLCA ([**Figure 2**](#f2){ref-type="fig"}).

![*Gene Set Enrichment Analysis* (GSEA) analysis between risk groups as classified by the immune-related gene (IRG)-based signature. **(A)** GSEA in gene ontology (GO) terms. **(B)** GSEA in Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways.](fgene-11-00012-g006){#f6}

Difference of Tumor-Infiltrating Immune Cells Between Risk Groups {#s3_5}
-----------------------------------------------------------------

We analyzed the difference in tumor-infiltrating immune cells in TCGA samples between the risk groups to explore the relationship between the present IRG-based prognostic signature and the tumor immune microenvironment. The results showed that abundance of six types of tumor-infiltrating immune cells except B cells were significantly enriched (P \< 0.001) in the high risk group as compared to the low risk group by Wilcoxon test. By contrast, higher B cell level was observed in the low-risk group (P \< 0.001) ([**Figure 7**](#f7){ref-type="fig"}).

![The difference of tumor-infiltrating immune cells among risk groups as defined by the seven immune‐related gene (7-IRG) prognostic signature.](fgene-11-00012-g007){#f7}

Construction of a Nomogram Based on the Seven Immune-Related Gene Signature {#s3_6}
---------------------------------------------------------------------------

We developed a nomogram to predict 1-, 3-, and 5-year overall survival using the 7-IRG signature and the aforementioned clinical factors of colorectal cancer ([**Figure 8A**](#f8){ref-type="fig"}). The ROC analysis ([**Figure 8B**](#f8){ref-type="fig"}) showed adequate discrimination with an AUC of 0.759, and 0.783 at 3- and 5-year follow-up, indicating that the nomogram could distinguish over 75% of survival outcome at these time-points. In addition, the calibration plot ([**Figure 8C-D**](#f8){ref-type="fig"}) demonstrated optimal predictive accuracy with predicted survival rate approximately equivalent to actual survival. Further, results of DCA ([**Figure 8E-F**](#f8){ref-type="fig"}) showed that most of the dashed curve were above the two solid lines (black and gray), suggesting positive net benefits. In other words, clinical decision made upon the nomogram would be favorable than treat-none or treat-all scheme.

![Construction of a nomogram based on the seven immune‐related gene (7-IRG) signature. **(A)** A nomogram based on the signature and clinical information. **(B)** Time-dependent receiver operating characteristic (ROC) curve for predicting overall survival (OS) of the nomogram. **(C, D)** Calibration plot evaluating the predictive accuracy of the nomogram \[at 3-year survival **(C)** at 5-year survival **(D)**\]. **(E, F)** Decision curve analysis evaluating the clinical utility of the nomogram \[at 3-year survival **(E)** at 5-year survival **(F)**\].](fgene-11-00012-g008){#f8}

Discussion {#s3_7}
----------

BLCA patients are at substantial risk for recurrence and metastasis. Over the past several decades, treatments for metastatic BLCA remained unsatisfied with platinum chemotherapy until immune checkpoint therapy came up ([@B31]; [@B32]; [@B33]). With the growing popularity of immunotherapy, attention has been shifting to developing novel biomarkers related to tumor immune milieus for estimates of treatment response and survival outcome ([@B34]).

Till date, no report on IRG-based prognostic signatures exists, although considerable efforts have been made to develop prognostic signatures based on differentially expressed genes ([@B35]; [@B36]; [@B37]). We identified seven prognostic IRGs based on a comprehensive analysis which could serve as valuable biomarkers in the clinical setting. Further, the prognostic signature based on the seven IRGs could categorize BLCA patients into two subgroups with statistically different survival outcomes, which was validated in both TCGA and GSE13507 datasets. Multivariate Cox analysis indicated that the IRG-based prognostic signature was independent of clinical factors. Further, it presented discrimination in overall survival rate, cancer-specific survival and progression-free survival in GSE13507 cohort, indicating the 7-IRG prognostic signature was independent of datasets. Using the 7-IRG signature along with age, gender and TNM_stage, we built a nomogram to predict overall survival for patients with BLCA. The nomogram promised to be clinically-relevant and credible in predictive performance. Additionally, we explored the underlying mechanisms using GSEA and immune cell analysis between risk groups. These findings support the potential translation of the present IRG-based prognostic signatures into clinical practice.

Our IRG-based signature highlighted seven IRGs, i.e., RBP7, PDGFRA, AHNAK, OAS1, RAC3, EDNRA, and SH3BP2. Expression of PDGFRA was reported in BLCA specimens; however, such report lacked sufficient experimental study ([@B38]; [@B39]). AHNAK was identified as a unique intracellular protein with different expression level and subcellular localization between BLCA sample and control ([@B40]); whereas, its prognostic value was observed in other studies ([@B41]; [@B42]). High expression of EDNRA was found to be associated with poor outcome in patients with advanced BLCA in a bioinformatics report ([@B43]). By contrast, no reports concerning RBP7, OAS1, RAC3, and SH3BP2 were published in BLCA, and therefore, the role of these IRGs in BLCA requires further investigation.

To explore the mechanisms by which the IRG-based signature effectively stratifies BLCA patients, GSEA between risk groups as classified by the signature demonstrated significant activity of multiple immune-related pathways in the high-risk patients. DEGs between risk groups were significantly enriched in chemokine signaling pathway and cytokine-receptor interaction, which are involved in chemotaxis, angiogenesis, as well as inflammatory processes ([@B44]; [@B18]). The cytokines play a crucial role in the immune response of cytotoxic T lymphocytes (CTL), and the regulation of cellular differentiation ([@B45]). Besides, an enhanced inflammatory milieu is reported to be associated with tumor progression and poor prognosis ([@B46]; [@B44]). To further elucidate the role of tumor milieu associated with the 7-IRG signature, we analyzed the estimations of six types of immune cells and observed increased abundance of CD4+ T cells, CD8+ T cells, macrophage, neutrophil and dendritic cells in the high-risk group. T cells infiltration was reported to promote tumor invasion and metastasis *via* the androgen receptor ([@B47]) and estrogen receptor signaling ([@B48]) among BLCA patients. This aspect aligned with a clinical study that demonstrated the prognostic role of a specific subset of CD4+ T cells (Th17) ([@B49]). The infiltration of tumor-associated macrophages is recognized to facilitate tumor progression in BLCA *via* tumorigenesis, angiogenesis, and disruption of adaptive immune response ([@B50]). Moreover, the recruitment of neutrophils could increase the level of human neutrophil peptides, which cause tumor angiogenesis and growth ([@B51]). An increase of tumor-infiltrating neutrophils was linked to immunosuppression in muscle invasion of BLCA patients that lead to inadequate treatment response and prognosis ([@B52]). Additionally, the presence of tumor-infiltrated dendritic cells is associated with tumor progression and poor prognosis. By contrast, higher B cell level in the low-risk group indicated the tumor-suppressive role of B cell infiltration, which was consistent with a previous study ([@B53]). In summary, the misregulation of tumor immune microenvironment may be responsible for the difference in survival outcome observed between groups as defined by the prognostic signature.

In the present study, we reported a prognostic signature based on IRG expression for predicting survival rate in BLCA patients, which was observed to be clinically relevant and effective in different datasets. To our best knowledge, this has been the first reported IRG-based signature in BLCA. Nevertheless, our results consisted of several limitations. First, as non-tumor samples were less than BLCA specimen, the results were biased to an extent. Second, the molecular mechanisms of BLCA could not be fully elucidated due to lack of *in vitro* and *in vivo* studies. Further studies are therefore warranted.

Conclusions {#s4}
===========

We developed and validated a first-ever IRG-based prognostic signature that stratify BLCA patients into two subgroups with statistically different survival outcomes, for which misregulation of tumor immune microenvironment might be responsible. These findings may provide insight on development of novel immune biomarkers and target therapy.
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Differentially expressed genes between BLCA samples and non-tumor samples.

###### 

Click here for additional data file.
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Boxplot of expression levels in these genes between BLCA and normal samples in TCGA dataset with results of Wilcoxon test.
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Click here for additional data file.

###### 

Riskplots for the 7-IRG signature in GSE13507 \[(1)overall survival; (2) cancer-specific survival; (3) progression-free survival\] **(A)** Heatmap of expression profiles of included IRGs **(B)** Distribution of groups based on the signature (C) Survival status of patients in different groups.
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